Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duloxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 0.87 |
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.87 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.87 |
| ▸ | MLNR | O43193 | 1/20 | 0.87 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.87 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.87 |
| ▸ | HTR1A | P08908 | 1/20 | 0.87 |
| ▸ | GAA | P10253 | 1/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.87 |
| ▸ | DRD2 | P14416 | 1/20 | 0.87 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.87 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.87 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.87 |
| ▸ | HTR2A | P28223 | 1/20 | 0.87 |
| ▸ | HTR2C | P28335 | 1/20 | 0.87 |
| ▸ | MC4R | P32245 | 1/20 | 0.87 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duloxetine SCHEMBL3335 | 1.00 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3896385 | 1.00 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL2120068 | 0.96 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL4573554 | 0.95 | SLC6A2 (0.85) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL309402 | 0.94 | SLC6A2 (0.83) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL2109339 | 0.94 | SLC6A2 (0.87) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL991500 | 0.93 | SLC6A2 (0.95) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3803 | 0.93 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3398599 | 0.93 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL8291 | 0.93 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3MLNRCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799935-B2 | Crystalline duloxetine hydrochloride | Chongqing Shenghuaxi Pharmaceuticals Co. Ltd. (CN) | 2010-09-21 | — | — | US | claimed |
| US-7795455-B2 | dissolving duloxetine in a first organic solvent (e.g.ethyl acetate) to form a first solution; adding the first solution to a second organic solvent (e.g.ethanol) comprising HCl to form a second solution;allowing duloxetine hydrochloride to crystallize out from second solution; collecting the product | Chongqing Shenghuaxi Pharmaceuticals Co. Ltd. (CN) | 2010-09-14 | — | — | US | claimed |
| US-7795454-B2 | Crystalline duloxetine hydrochloride | Chongqing Shenghuaxi Pharmaceuticals Co. Ltd. (CN) | 2010-09-14 | — | — | US | claimed |
| EP-1745031-B1 | CRYSTALLINE FORMS OF DULOXETINE FREE BASE | CIPLA LTD (IN) | 2010-03-10 | — | — | EP | claimed |
| EP-2049512-A2 | CRYSTALLINE DULOXETINE HYDROCHLORIDE | Arrow International Limited (MT) | 2009-04-22 | — | — | EP | claimed |
| EP-2035404-A1 | CRYSTALLINE DULOXETINE HYDROCHLORIDE | Arrow International Limited (MT) | 2009-03-18 | — | — | EP | claimed |
| EP-2035403-A1 | CRYSTALLINE DULOXETINE HYDROCHLORIDE | Arrow International Limited (MT) | 2009-03-18 | — | — | EP | claimed |
| US-20090012315-A1 | Process for Pure Duloxetine Hydrochloride | MSN LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | claimed |
| EP-1976844-A2 | IMPROVED PROCESS FOR PURE DULOXETINE HYDROCHLORIDE | MSN Laboratories Limited (IN) | 2008-10-08 | — | — | EP | claimed |
| US-20080021089-A1 | Crystalline duloxetine hydrochloride | ARROW INTERNATIONAL LIMITED (MT) | 2008-01-24 | — | — | US | claimed |
| WO-2007148102-A2 | CRYSTALLINE DULOXETINE HYDROCHLORIDE | ARROW INTERNATIONAL LIMITED (MT) | 2007-12-27 | — | — | WO | claimed |
| WO-2007148096-A1 | CRYSTALLINE DULOXETINE HYDROCHLORIDE | ARROW INTERNATIONAL LIMITED (MT) | 2007-12-27 | — | — | WO | claimed |
| WO-2007148103-A1 | CRYSTALLINE DULOXETINE HYDROCHLORIDE | ARROW INTERNATIONAL LIMITED (MT) | 2007-12-27 | — | — | WO | claimed |
| EP-1587802-B1 | PRODUCTION AND USE OF 3-METHYLAMINO-1-(2-THIENYL)-1-PROPANONE | BASF AG (DE) | 2007-11-14 | — | — | EP | claimed |
| US-7259264-B2 | 3-methylamino-1-(2-thienyl)-1-propanone, production and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-21 | — | — | US | claimed |
| US-20070167513-A1 | Crystalline forms of duloxetine free base | CIPLA LIMITED (IN) | 2007-07-19 | — | — | US | claimed |
| WO-2007077580-A2 | IMPROVED PROCESS FOR PURE DULOXETINE HYDROCHLORIDE | MSN LABORATORIES LIMITED (IN) | 2007-07-12 | — | — | WO | claimed |
| EP-1745031-A1 | CRYSTALLINE FORMS OF DULOXETINE FREE BASE | Cipla Ltd. (IN) | 2007-01-24 | — | — | EP | claimed |
| US-20060128791-A1 | 3-Methylamino-1-(2-thienyl)-1-propanone, production and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-15 | — | — | US | claimed |
| WO-2005108386-A1 | CRYSTALLINE FORMS OF DULOXETINE FREE BASE | CIPLA LIMITED (IN) | 2005-11-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012315-A1 | Process for Pure Duloxetine Hydrochloride | OPRK1, OPRM1, OPRD1 | SLC6A2 6/4885SLC6A4 5/4885SLC6A3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.